Anima

Foundation date

01/12/2018

Sector

#Biotechnology / R&D Services

Subsector

Therapeutic areas

ANT01, a Phase IIa proprietary small molecule in the Prevention of Alzheimer Disease in well defined patients, is oriented to prevent in the US only at least 100.000 new AD cases per year by treatment of 1M patients life time. After 5 years of planned launch in 2030 and with a peak sales of 10B, this will save US healthcare costs by at least 50B giving ANT01 a very attractive value proposition.

Upcoming events

Latest news

  • Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease

    1 day ago

  • Bone Therapeutics receives EUR 1.0 million to advance ongoing JTA-004 phase III knee osteoarthritis study

    1 day ago

  • BISC Global opens in Switzerland

    Wednesday August 12th 2020